An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis

drug protocol number

B7841005

drug sponsor

Pfizer

drug study

PF-06741086

drug trial site

King Abdulaziz University Hospital (Jeddah)

drug status

Ongoing

drug phase